Study of Tamoxifen and Raloxifene explained

The Study of Tamoxifen and Raloxifene (STAR) is a clinical trial from the early 2000s designed determine how the drug raloxifene compares with the drug tamoxifen in reducing the incidence of breast cancer in women who are at increased risk of the disease.^[1]

Research

One of the largest breast cancer prevention studies ever,^[2] it included 22,000 women in 400 medical centers in the United States and Canada.^{[3] [4] [5]}

The study concluded that raloxifene caused fewer side-effects and less endometrial cancer than tamoxifen.^{[6] [7]} Raloxifene was found to be more effective at preventing noninvasive breast cancer but less effective at preventing invasive breast cancer.^[8]

External links

• Study of Tamoxifen and Raloxifene (STAR) Trial

Notes and References

1. Web site: Study of Tamoxifen and Raloxifene (STAR) . Weill Cornell Medical College .
2. http://www.post-gazette.com/pg/06108/682975-114.stm "Osteoporosis drug equals tamoxifen in preventing breast cancer"
3. https://www.nytimes.com/1999/06/16/us/drug-slashes-breast-cancer-risk-study-shows.html "Drug Slashes Breast Cancer Risk, Study Shows"
4. Web site: Wickerham L . What is the Study of Tamoxifen and Raloxifene Breast Cancer Prevention Trial? . ABC News .
5. Web site: Study of Tamoxifen and Raloxifene (STAR) . Columbia St. Mary's .
6. Web site: Teleconference: Study of Tamoxifen and Raloxifene (STAR) P-2 . 19 April 2010 . American Association for Cancer Research .
7. https://www.usatoday.com/news/health/2006-04-17-q-and-a-drug_x.htm "Raloxifene or tamoxifen: Which is the right drug for you?"
8. http://www.businessweek.com/lifestyle/content/healthday/638233.html "Raloxifene, Tamoxifen Both Guard Against Breast Cancer"